Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.

M C U CheangJ M BlissG VialeV SpeirsC PalmieriA ShaabanP E LønningJ MordenN PortaJ JassemC J van De VeldeB B RasmussenD VerhoevenJ M S BartlettRaoul Charles Coombesnull null

Published in: Breast cancer research and treatment (2017)

In the PathIES population, the IHC4 score is useful in predicting long-term relapse in patients who remain disease-free after 2-3 years. This is a first trial to suggest the extending use of IHC4+C score for prognostic indication for patients who have switched endocrine therapies at 2-3 years and who remain disease-free after 2-3 years.

Keyphrases

end stage renal disease
clinical trial
newly diagnosed
chronic kidney disease
randomized controlled trial
prognostic factors
open label